OvaScience Reports First Quarter 2014 Financial Results
Business Wire - Thu May 08, 6:01AM CDT
OvaScience(SM), (NASDAQ:OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, today reported first quarter 2014 financial results, and highlighted recent accomplishments.
OvaScience to Present at the 39th Annual Deutsche Bank Health Care Conference
Business Wire - Thu May 01, 7:30AM CDT
OvaScience(SM), (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that Michelle Dipp, M.D., Ph.D., Chief Executive of OvaScience, will present at the 39th Annual Deutsche Bank Securities Health Care Conference on Thursday, May 8, at 8:00am EDT in the InterContinental Boston Hotel.
OvaScience Co-Founder David Sinclair, Ph.D., Selected by TIME as one of the 100 Most Influential People in The World
Business Wire - Thu Apr 24, 7:03AM CDT
OvaScience(SM), (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, today announced that the Company's scientific Co-Founder, David Sinclair, Ph.D., has been selected for the 2014 TIME 100, TIME's annual list of the 100 most influential people in the world. Dr. Sinclair's extensive research on aging and the key role of mitochondria (the energy source for all cells) contributed to OvaScience's foundational egg precursor cell (EggPC(SM)) technology platform. The Company expects to launch its first fertility product, AUGMENT(SM), in international in vitro fertilization (IVF) clinics in 2014. AUGMENT is designed to improve egg quality and the success of IVF by enhancing mitochondrial function.
How OvaScience (OVAS) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 7:42AM CDT
OvaScience has been witnessing a significant price rise in the past month with a positive momentum in the earnings estimate front
OvaScience Announces Exercise of Over-Allotment Option in Public Offering of Common Stock
Business Wire - Tue Mar 18, 7:31AM CDT
OvaScience(SM), (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that the underwriters of its previously announced public offering of common stock have exercised their option to purchase an additional 518,630 shares of common stock at the public offering price of $10.00 per share. As a result, total gross proceeds to OvaScience from this offering are $55.2 million before deducting the underwriting discounts, commissions and estimated expenses.
OvaScience to Present at the 26th Annual ROTH Conference
Business Wire - Thu Mar 06, 7:31AM CST
OvaScience(SM), (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of female fertility treatments, today announced that Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience will present at the 26th Annual ROTH Conference on Tuesday, March 11 at 12:30pm Pacific Standard Time. The conference will take place at the Ritz-Carlton in Laguna Niguel, California.
OvaScience (OVAS) in Focus: Stock Tanks 9.5% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 7:48AM CST
OvaScience fell 9.5% last trading session, reversing the recent trend
Nasdaq stocks posting largest volume increases
AP - Tue Mar 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Nasdaq stocks posting largest percentage decreases
AP - Tue Mar 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
OvaScience Prices $50 Million Public Offering of Common Stock
Business Wire - Tue Mar 04, 7:35AM CST
OvaScience(SM), (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced the pricing of $10.00 per share for its previously announced underwritten public offering of 5,000,000 shares of its common stock. Gross proceeds to OvaScience from this offering are expected to be approximately $50 million, and the Company intends to use the net proceeds to fund OvaPrime(SM) preclinical studies and the anticipated 2015 international launch, establish an international subsidiary, expand the AUGMENT(SM) international launch, and for other general corporate purposes.
OvaScience Announces Proposed Public Offering of Common Stock
Business Wire - Mon Mar 03, 3:05PM CST
OvaScience(SM), (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today it has commenced an underwritten public offering of shares of its common stock. OvaScience intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering to cover over-allotments, if any. All of the shares in the offering will be sold by OvaScience.
OvaScience Reports Fourth Quarter and Year End 2013 Financial Results
Business Wire - Thu Feb 27, 7:30AM CST
OvaScience(SM), (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, today reported fourth quarter and year end 2013 financial results, and highlighted recent accomplishments.
OvaScience (OVAS) in Focus: Stock Up 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 8:39AM CST
OvaScience, Inc. (OVAS) was a big mover last session, as its shares rose nearly 6% on the day.
2 Health Care Stocks Under $10 to Trade
at The Street - Thu Feb 20, 5:00AM CST
These health care stocks under $10 were trading higher on Wednesday. Here's how to trade them now.
OvaScience Issued Two U.S. Patents Covering AUGMENT(SM) Fertility Treatment
Business Wire - Wed Feb 12, 7:30AM CST
OvaScience(SM) (NASDAQ:OVAS), a life sciences company focused on the discovery, development and commercialization of female fertility treatments, today announced the issuance of two United States patents covering its AUGMENT(SM) fertility treatment. AUGMENT is based on the Company's egg precursor cell (EggPC(SM)) technology and is being developed to improve egg quality and the success of in vitro fertilization (IVF). AUGMENT will be available in international IVF clinics this year.
OvaScience Appoints Fertility Pioneer Jamie Grifo M.D., Ph.D., to Clinical Advisory Board
Business Wire - Tue Feb 04, 7:30AM CST
OvaScience(SM), (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of female fertility treatments, announced today the appointment of Jamie Grifo, M.D., Ph.D., of the New York University (NYU) Fertility Center and the Division of Reproductive Endocrinology at the NYU School of Medicine, to its Clinical Advisory Board.
OvaScience to Present at Upcoming Conferences
Business Wire - Mon Feb 03, 7:30AM CST
OvaScience(SM), (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of female fertility treatments, today announced that the Company's management team will present at two upcoming conferences in February. The conference and OvaScience presentation details are as follows:
OvaScience (OVAS) in Focus: Stock Tumbles 7.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 7:34AM CST
OvaScience stock tumbles 8% yesterday, continuing the recent downtrend
OvaScience Provides Update on Pipeline Advancements and Commercial Plans; New Potential Fertility Treatment OvaPrime(SM) to Launch in 2015
Business Wire - Mon Jan 13, 7:30AM CST
OvaScience(SM), (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of female fertility treatments, today provided an update on its product pipeline and commercial plans, which are based on its egg precursor cell (EggPC(SM)) technology platform. OvaScience expects to commercialize AUGMENT(SM) in international in vitro fertilization (IVF) clinics in 2014 and to launch its newest potential fertility treatment, OvaPrime(SM), in 2015.